Ignite Creation Date:
2024-05-06 @ 2:05 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04218344
Status:
RECRUITING
Last Update Posted:
2020-01-18
First Post:
2020-01-02
Brief Title:
The Harefield Acute Myocardial Infarction Cohort
Sponsor:
Royal Brompton Harefield NHS Foundation Trust
Organization:
Royal Brompton Harefield NHS Foundation Trust
Study Overview
Official Title:
The Harefield Acute Myocardial Infarction Cohort
Status:
RECRUITING
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEART - ACS
Brief Summary:
In this project the investigators plan to collect blood during a patients routine angiogram procedure which they will have due to having suffered a heart attack Data from the patients routine procedures for this condition including but not exclusively ECG Echocardiogram MRI scans will be collected The aim of the research project is to analyse the blood samples and identify novel biomarkers and clinical parameters associated with acute coronary syndromes The investigators will particularly focus on markers of inflammation and micro-organism activity The investigators hope that this will help to gain more knowledge about what causes heart disease and how various conditions can be treated more efficiently The investigators will follow-up and collect further research data via a questionnaire at the routine 6 weeks and 6 months follow-up appointment after the angiogram procedure Participants will also be telephoned at one-year post procedure to update any events and medication status and data will thereafter be collected form data held by the hospital without having to contact the participant Remaining blood samples will be stored securely for further analysis into blood and other markers
Detailed Description:
Acute coronary syndromes ACS ie patients presenting with ST-segment elevation myocardial infarction STEMI non ST-segment elevation myocardial infarction non-STEMI or unstable angina are still a major cause of morbidity and mortality in the United Kingdom and beyond In spite of the enormous progress made in the last decades the in hospital mortality has plateaued recently and the event rate after the infarction is still high with one in 8 patients having a second event ie death myocardial infarction heart failure revascularization among others within a year of follow-up
After the acute event risk stratification is important and will be come even more sophisticated than it currently is with the advent of anatomic risk scores SYNTAX II Score novel biomarkers and novel drugs allowing for more precise characterization of the patients individual risk and more tailored secondary prevention strategies Precision Medicine
Indeed particularly the upcoming treatment strategies with bio-logicals ie monoclonal antibodies eg against PCSK9 and genetic tools ie RNA interference antisense technology will require precise risk assessment for cost-effective use of these promising new tools
It is anticipated that this study will help the investigators to describe the heart attack population in a robust manner with a wealth of clinical data as well as blood samples for bio-markers
After the acute event risk stratification is important and will be come even more sophisticated than it currently is with the advent of anatomic risk scores SYNTAX II Score novel biomarkers and novel drugs allowing for more precise characterization of the patients individual risk and more tailored secondary prevention strategies Precision Medicine
Indeed particularly the upcoming treatment strategies with bio-logicals ie monoclonal antibodies eg against PCSK9 and genetic tools ie RNA interference antisense technology will require precise risk assessment for cost-effective use of these promising new tools
It is anticipated that this study will help the investigators to describe the heart attack population in a robust manner with a wealth of clinical data as well as blood samples for bio-markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None